Inflammatory biomarkers and bladder cancer prognosis: A systematic review

European Urology

Volumn 66, Issue 6, 2014, Pages 1078-1091

  Masson Lecomte, Alexandra ^a,b   Rava, Marta ^a   Real, Francisco X ^a,c   Hartmann, Arndt ^d   Allory, Yves ^a,b   Malats, Núria ^a  

^a Structural Biology and Biocomputing Programme   (Spain)

^b INSERM   (France)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Biomarkers; Bladder cancer; Inflammation; Progression; Survival

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD3 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CD83 ANTIGEN; CYTOKINE; DNA; TRANSCRIPTION FACTOR FOXP3; AUTACOID; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; GENETIC MARKER; INTERLEUKIN 6; LEUKOCYTE ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

BLADDER CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; DIAGNOSTIC TEST ACCURACY STUDY; EMBASE; GENE OVEREXPRESSION; GERM LINE; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; MEDLINE; METHODOLOGY; NEUTROPHIL LYMPHOCYTE RATIO; PATIENT CARE; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; TUMOR CELL; TUMOR MICROENVIRONMENT; BLADDER TUMOR; BLOOD; CARCINOMA; CD8+ T LYMPHOCYTE; CHEMISTRY; GENETIC MARKER; GENETICS; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; MORTALITY; NEUTROPHIL; PROGNOSIS;

ANTIGENS, CD; ANTIGENS, CD274; BIOMARKERS, TUMOR; C-REACTIVE PROTEIN; CARCINOMA; CD8-POSITIVE T-LYMPHOCYTES; FORKHEAD TRANSCRIPTION FACTORS; GENETIC MARKERS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LYMPHOCYTE COUNT; NEUTROPHILS; PROGNOSIS; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER NEOPLASMS;

EID: 84909946537     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.07.033     Document Type: Review

References (67)

1. D. Hanahan, and L.M. Coussens Accessories to the crime: functions of cells recruited to the tumor microenvironment Cancer Cell 21 2012 309 322
2. W.H. Fridman, F. Pages, C. Sautes-Fridman, and J. Galon The immune contexture in human tumours: impact on clinical outcome Nat Rev Cancer 12 2013 298 306
3. J. Galon, F. Pages, and F.M. Marincola Cancer classification using the Immunoscore: a worldwide task force J Transl Med 10 2012 205
4. C. Denkert, S. Loibl, and A. Noske Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer J Clin Oncol 28 2010 105 113
5. J. Galon, A. Costes, and F. Sanchez-Cabo Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 2006 1960 1964
6. E. Wang, L.D. Miller, and G.A. Ohnmacht Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness Cancer Res 62 2002 3581 3586
7. F. Kunath, S.F. Krause, and B. Wullich Bladder cancer - the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register clinicaltrials.gov BMC Urol 13 2013 56
8. W.J. Catalona, J.K. Smolev, and J.I. Harty Prognostic value of host immunocompetence in urologic cancer patients J Urol 114 1975 922 926
9. I. Romics, J. Feher, and J. Horvath Immunological studies of patients with tumours of the prostate and bladder (a retrospective analysis) Int Urol Nephrol 15 1983 339 345
10. N. Sadoughi, J. Mlsna, P. Guinan, and A. Rubenstone Prognostic value of cell surface antigens using immunoperoxidase methods in bladder carcinoma Urology 20 1982 143 146
11. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark Reporting recommendations for tumor marker prognostic studies J Clin Oncol 23 2005 9067 9072
12. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558
13. J. Lau, J.P. Ioannidis, N. Terrin, C.H. Schmid, and I. Olkin The case of the misleading funnel plot BMJ 333 2006 597 600
14. M.J. Czachorowski, A.F. Amaral, and S. Montes-Moreno Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis PLoS One 7 2012 e45025
15. D. Ahirwar, P. Kesarwani, P.K. Manchanda, A. Mandhani, and R.D. Mittal Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guerin immunotherapy in bladder cancer Cancer Genet Cytogenet 184 2008 1 8
16. D. Leibovici, H.B. Grossman, and C.P. Dinney Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival J Clin Oncol 23 2005 5746 5756
17. D.K. Ahirwar, A. Agrahari, A. Mandhani, and R.D. Mittal Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy Biomarkers 14 2009 213 218
18. G. Gakis, T. Todenhofer, and M. Renninger Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score BJU Int 108 2011 1800 1805
19. T. Gondo, J. Nakashima, and Y. Ohno Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy Urology 79 2012 1085 1091
20. M. Hilmy, R. Campbell, J.M. Bartlett, A.M. McNicol, M.A. Underwood, and D.C. McMillan The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder Br J Cancer 95 2006 1234 1238
21. E.C. Hwang, I.S. Hwang, and H.S. Yu Utility of inflammation-based prognostic scoring in patients given systemic chemotherapy first-line for advanced inoperable bladder cancer Jpn J Clin Oncol 42 2012 955 960
22. J. Ishioka, K. Saito, and M. Sakura Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis Br J Cancer 107 2012 1031 1036
23. T. Nakagawa, T. Hara, and T. Kawahara Prognostic risk stratification of patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy J Urol. 189 2013 1275 1281
24. K. Saito, S. Urakami, and Y. Komai Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin BJU Int 110 2012 1478 1484
25. S. Yoshida, K. Saito, and F. Koga C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy BJU Int 101 2008 978 981
26. C.T. Lin, C.L. Tung, and Y.S. Tsai Prognostic relevance of preoperative circulating CD8-positive lymphocytes in the urinary bladder recurrence of urothelial carcinoma Urol Oncol 30 2012 680 687
27. L.S. Krane, K.A. Richards, A.K. Kader, R. Davis, K.C. Balaji, and A.K. Hemal Preoperative neutrophil/lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystectomy J Endourol 27 2013 1046 1050
28. P. Sharma, Y. Shen, and S. Wen CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma Proc Natl Acad Sci U S A 104 2007 3967 3972
29. M.E. Winerdal, P. Marits, and M. Winerdal FOXP3 and survival in urinary bladder cancer BJU Int 108 2011 1672 1678
30. T. Cai, G. Nesi, V. Boddi, S. Mazzoli, M. Dal Canto, and R. Bartoletti Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma Oncol Rep 16 2006 329 334
31. J. Flamm, and L. Havelec Factors affecting survival in primary superficial bladder cancer Eur Urol 17 1990 113 118
32. B.V. Offersen, M.M. Knap, N. Marcussen, M.R. Horsman, S. Hamilton-Dutoit, and J. Overgaard Intense inflammation in bladder carcinoma is associated with angiogenesis and indicates good prognosis Br J Cancer 87 2002 1422 1430
33. H. Samaratunga, P. Fairweather, and D. Purdie Significance of stromal reaction patterns in invasive urothelial carcinoma Am J Clin Pathol 123 2005 851 857
34. P. Sanchez de la Muela, D. Rosell, and L. Aguera Superficial bladder cancer: survival and prognostic factors Eur Urol 20 1991 184 191
35. J. Flamm The value of tumor-associated tissue inflammatory reaction in primary superficial bladder cancer Urol Res 18 1990 113 117
36. C. Ayari, H. LaRue, and H. Hovington Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy Eur Urol 55 2009 1386 1396
37. C. Ayari, H. LaRue, and H. Hovington High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer Hum Pathol 44 2013 1630 1637
38. H. Takayama, K. Nishimura, and A. Tsujimura Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation J Urol 181 2009 1894 1900
39. T. Hanada, M. Nakagawa, A. Emoto, T. Nomura, N. Nasu, and Y. Nomura Prognostic value of tumor-associated macrophage count in human bladder cancer Int J Urol 7 2000 263 269
40. S. Hori, T. Nomura, and S. Sakaguchi Control of regulatory T cell development by the transcription factor Foxp3 Science 299 2003 1057 1061
41. H. Kitamura, T. Torigoe, and I. Honma Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus Calmette-Guerin immunotherapy for bladder cancer Clin Cancer Res 12 2006 4641 4644
42. S.A. Boorjian, Y. Sheinin, and P.L. Crispen T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival Clin Cancer Res 14 2008 4800 4808
43. J. Nakanishi, Y. Wada, K. Matsumoto, M. Azuma, K. Kikuchi, and S. Ueda Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers Cancer Immunol Immunother 56 2007 1173 1182
44. Y. Wang, Q. Zhuang, S. Zhou, Z. Hu, and R. Lan Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance J Huazhong Univ Sci Technolog Med Sci 29 2009 77 79
45. I. Levin, T. Klein, J. Goldstein, O. Kuperman, J. Kanetti, and B. Klein Expression of class I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival Cancer 68 1991 2591 2594
46. I. Homma, H. Kitamura, and T. Torigoe Human leukocyte antigen class I down-regulation in muscle-invasive bladder cancer: its association with clinical characteristics and survival after cystectomy Cancer Sci 100 2009 2331 2334
47. S.K. Calderwood, A. Murshid, and J. Gong Heat shock proteins: conditional mediators of inflammation in tumor immunity Front Immunol 3 2012 75
48. K.N. Syrigos, K.J. Harrington, and A.J. Karayiannakis Clinical significance of heat shock protein-70 expression in bladder cancer Urology 61 2003 677 680
49. H.J. Yu, Y.H. Chang, and C.C. Pan Prognostic significance of heat shock proteins in urothelial carcinoma of the urinary bladder Histopathology 62 2013 788 798
50. N. Malats, A. Bustos, and C.M. Nascimento P53 as a prognostic marker for bladder cancer: a meta-analysis and review Lancet Oncol 6 2005 678 686
51. G. Sjodahl, M. Lauss, and K. Lovgren A molecular taxonomy for urothelial carcinoma Clin Cancer Res 18 2012 3377 3386
52. J.P. Volkmer, D. Sahoo, and R.K. Chin Three differentiation states risk-stratify bladder cancer into distinct subtypes Proc Natl Acad Sci U S A 109 2012 2078 2083
53. S.F. Shariat, Y. Lotan, and A. Vickers Statistical consideration for clinical biomarker research in bladder cancer Urol Oncol 28 2010 389 400
54. G. Tripepi, K.J. Jager, F.W. Dekker, and C. Zoccali Statistical methods for the assessment of prognostic biomarkers (part I): discrimination Nephrol Dial Transplant 25 2010 1399 1401
55. E.L. de Maturana, Y. Ye, and M.L. Calle Application of multi-SNP approaches bayesian LASSO and AUC-RF to detect main effects of inflammatory-gene variants associated with bladder cancer risk PLoS One 8 2013 e83745
56. O. Dalpiaz, M. Pichler, and S. Mannweiler Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma Br J Cancer 110 2014 2531 2536
57. B.R. Viers, S.A. Boorjian, and I. Frank Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy Eur Urol 66 2014 1157 1164
58. Y. Wei, Y.Z. Jiang, and W.H. Qian Prognostic role of NLR in urinary cancers: a meta-analysis. PLoS One 2014; 9 2014 e92079
59. F. Pages, A. Kirilovsky, and B. Mlecnik In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer J Clin Oncol 27 2009 5944 5951
60. G. Sjodahl, M. Lauss, and K. Lovgren A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 2012; 18 2012 3377 3386
61. M.J. Butte, V. Pena-Cruz, M.J. Kim, G.J. Freeman, and A.H. Sharpe Interaction of human PD-L1 and B7-1 Mol Immunol 45 2008 3567 3572
62. M.J. Butte, M.E. Keir, T.B. Phamduy, A.H. Sharpe, and G.J. Freeman Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses Immunity 27 2007 111 122
63. J.R. Brahmer, S.S. Tykodi, and L.Q. Chow Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
64. A.M. Eggermont, A. Spatz, and C. Robert Cutaneous melanoma Lancet 383 2014 816 827
65. B.P. Schrier, M.P. Hollander, B.W. van Rhijn, L.A. Kiemeney, and J.A. Witjes Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy Eur Urol 45 2004 292 296
66. B. Andrews, S.F. Shariat, J.H. Kim, T.M. Wheeler, K.M. Slawin, and S.P. Lerner Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer J Urol 167 2002 1475 1481
67. W. Otto, S. Denzinger, W.F. Wieland, and A. Hartmann First analysis of immune cell infiltration in stage pT1 urothelial bladder carcinoma: CD3 positivity as a prognostic marker for cancer-specific survival World J Urol 30 2012 875 877